Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia

X
Trial Profile

A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 05 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Plozasiran (Primary)
  • Indications Hypertriglyceridaemia
  • Focus Therapeutic Use
  • Acronyms SHASTA-2
  • Sponsors Arrowhead Pharmaceuticals
  • Most Recent Events

    • 29 Apr 2024 According to an Arrowhead Pharmaceuticals media release, data from this trial will be presented at the 2024 National Lipid Association (NLA) Scientific Sessions - May 30 -June 2, 2024 and European Atherosclerosis Society (EAS) 92nd Congress -May 26-29, 2024.
    • 07 Apr 2024 According to an Arrowhead Pharmaceuticals media release, final data from this study were presented at the American College of Cardiology 73rd Annual Scientific Session & Expo (ACC.24) in Atlanta and simultaneously published in the journal JAMA Cardiology.
    • 07 Apr 2024 Results presented in an Arrowhead Pharmaceuticals Media Release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top